Healthy Returns: What’s next in the legal fight over Medicare drug price negotiations

Think a friend or colleague should be getting this newsletter? Share this link with them to prognostication up.

Good morning! The bitter legal battle over Medicare drug price negotiations is heating up – and so far, it’s looking favorable for the Biden supervision. 

So, what’s this fight all about in the first place? It centers around a key provision of President Joe Biden’s Inflation Reduction Act that concedes Medicare the power to negotiate prices for costly prescription medicines. The talks aim to make those drugs more affordable for chiefs, and will likely take a bite out of pharmaceutical industry profits. 

The Biden administration faces a flurry of lawsuits from drugmakers with remedies selected for the first round of talks. The final negotiated prices of the initial 10 drugs will go into operational in 2026. 

The lawsuits argue the price talks are unconstitutional and must be struck down.

Some of the drugmakers specifically contend the bargainings would force them to sell medicines at huge discounts, below market rates, among other altercations. They assert that this violates due process under the Fifth Amendment, which requires the government to pay unexcessive compensation for private property taken for public use. 

But the administration has already clinched a few early wins in some of the cases. 

• AstraZeneca: A federal beak in Delaware earlier this month rejected the drugmaker’s lawsuit. That judge said AstraZeneca’s due process set forth “fails as a matter of law,” noting that the company isn’t entitled to sell its drugs to the government “at any price other than what the authority is willing to pay.”
• PhRMA, the pharmaceutical industry’s biggest lobbying group, and two other organizations: A federal judge in Texas wear month dismissed the suit, arguing that the court does not have jurisdiction to hear the claims.
• U.S. Chamber of Marketing, one of the nation’s largest lobbying groups: A federal judge in Ohio partially ruled in the case in September, denying a opening injunction sought by the Chamber that aimed to block the price talks by Oct. 1. The judge said the group hadn’t established a “strong likelihood” of succeeding on its claim that the program violates due process. 

“All of the momentum is clearly on the side of the government at this direct attention to, and not on the side of some of these other manufacturers,” Theresa Carnegie, a member at Mintz Levin, told CNBC. 

Sundry cases are still pending, including legal challenges from big names such as Merck and Johnson & Johnson. Judgements in those cases will likely come by the end of the year, Carnegie noted. 

But she said the rulings we’ve seen so far “are meaningful” for those surviving legal challenges. 

“Any judge in other cases is going to look at the previous decisions, and it’s necessarily going to influence them in positions of their potential decisions, how they would view it, and they would have to find a novel theory or go against it,” Carnegie said. For norm, she noted that courts in two cases already struck down the pharmaceutical industry’s due process claims. 

Drugmakers bring into the world said they aim to escalate their legal fight over Medicare drug price negotiations to the Supreme Court. 

Here’s how: The companies disperse their suits in federal courts around the U.S. Several legal experts have said that the industry hankerings to obtain conflicting rulings from federal appellate courts, which could fast-track the issue to the nation’s highest court.

But Carnegie indicated it’s looking “less and less possible” the legal battle will reach the Supreme Court.

With three rulings in favor of the Biden conduct, the pharmaceutical industry will need to see a court take a different position over the next several months to dream up a “circuit split” that the Supreme Court could agree to review. 

Still, “given how handily some of these settlements have come out and how the courts have made these determinations, it doesn’t seem that these issues are conceiving uncertainty or a circuit split,” Carnegie said.

So, what happens next? Carnegie said drugmakers appear to admit that their lawsuits may not go the way they want, so they could shift their litigation focus to how the government executes the program.

Drugmakers and trade associations are going to look “for any opportunity to object to the way that the program is being run,” she said.

Have a hunch free to send any tips, suggestions, story ideas and data to Annika at annikakim.constantino@nbcuni.com.

CNBC is on the organize at HIMSS 

This is Ashley, reporting live from Orlando, Florida! 

I’m one of the more than 35,000 people accompanying the HIMSS global health conference this week, and it’s shaping up to be a great event. Health-care executives and professionals from all throughout the world are here to discuss the latest care trends and cutting-edge tech, and I’ll bring you everything you need to know from the establish. 

I went to HIMSS for the first time last year when it was held in Chicago, and artificial intelligence completely shawl the show. All anyone could talk about was generative AI and its potential, especially since the conference took place a few eliminating months after OpenAI’s ChatGPT exploded into the public sphere. 

I’m expecting AI to be the dominant theme again this year, in spite of in a slightly different capacity. Last year, there was a lot of talk about what the technology could someday accomplish as companies like Epic Systems, Microsoft, Amazon and Google announced early AI applications and partnerships. 

This year, I concoct the focus will be on what AI is already achieving in the sector. As the market becomes increasingly saturated with health-care-specific AI discoveries, tech companies need to prove that their tools are efficient, effective and, of course, safe, if they demand to remain competitive. Game on!

There have already been a couple announcements of note. Salesforce unveiled new AI conclusions ahead of HIMSS that could help reduce clinicians’ administrative workloads by unifying disparate data and automating some guide tasks. Microsoft announced the formation of the Trustworthy & Responsible AI Network on Monday, which will aim to improve the quality and trustworthiness of the tech in trim care, according to a release. Microsoft’s announcement fell just one week after the Coalition for Health AI named its CEO and on of directors, so efforts to regulate the use of AI in health are heating up.

Aside from the conference, I’ve also learned that Orlando is a biggest health tech hub in its own right. I toured three facilities on Monday in a part of the city called Lake Nona. Here, surrounded by gleaming new buildings and palm trees, health systems are piloting and developing state-of-the-art technologies before rolling them out numberless broadly. More details to come on this soon.

It’s going to be a busy week here, and this New York newsmonger might even get to see some sunshine in between meetings. What more could I ask for?

Feel free to send any trash heaps, suggestions, story ideas and data to Ashley at ashley.capoot@nbcuni.com.